An RNA polymerase inhibitor, cyclothiazomycin B1, and its isomer

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 24, 2006, Pages 8259-8270

  Hashimoto, Masaru ^a,b   Murakami, Takanori ^a,b   Funahashi, Katsuyuki ^a   Tokunaga, Takashi ^a   Nihei, Ken ichi ^a   Okuno, Toshikatsu ^d   Kimura, Takatsugu ^a,b   Naoki, Hideo ^c   Himeno, Hyouta ^a,b  

^a HIROSAKI UNIVERSITY   (Japan)

^b IWATE UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d Akita University of Nursing and Welfare   (Japan)

Author keywords

Cyclic thiopeptide; Cyclothiazomycin B; Isomerization of dehydrohomoalanine; RNA polymerase inhibition

Indexed keywords

ANTIBIOTIC AGENT; CYCLOTHIAZOMYCIN B1; CYCLOTHIAZOMYCIN B2; ENZYME INHIBITOR; RNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BACTERIOPHAGE; CONTROLLED STUDY; DRUG ISOLATION; DRUG STRUCTURE; GENETIC TRANSCRIPTION; ISOMERIZATION; NONHUMAN; SOLID STATE; SPECTROSCOPY; STREPTOMYCES;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA-DIRECTED RNA POLYMERASES; ENZYME INHIBITORS; FERMENTATION; ISOMERISM; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; PEPTIDES, CYCLIC; RENIN; STREPTOMYCES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

STREPTOMYCES SP.;

EID: 33750502619     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.09.006     Document Type: Article

References (32)

1. Jones D., Metzger H.J., Schatz A., and Waksman S.A. Science 100 (1944) 103-105
2. Bagley M.C., Dale J.W., Merritt E.A., and Xiong X. Chem. Rev. 105 (2005) 685-714
3. Porse B.T., Leviev I., Mankin A.S., and Garrett R.A. J. Mol. Biol. 276 (1998) 391-404
4. Landini P., Soffientini A., Monti F., Lociuro S., Marzorati E., and Islam K. Biochemistry 35 (1996) 15288
5. Aoki M., Ohtsuka T., Yamada M., Ohba Y., Yoshizaki H., Yasuno H., Sano T., Watanabe J., Yokose K., and Seto H. J. Antibiot. 44 (1991) 582-588
6. Murakami T., Holt T.G., and Thompsom C.J. J. Bacteriol. 171 (1989) 1459
7. Aoki M., Ohtsuka T., Itezono Y., Yokose K., Furihata K., and Seto H. Tetrahedron Lett. 32 (1991) 217-220
8. Aoki M., Ohtsuka T., Itezono Y., Yokose K., Furihata K., and Seto H. Tetrahedron Lett. 32 (1991) 221-224
9. Nihei K., Itoh H., Hashimoto K., Miyairi K., and Okuno T. Biosci. Biotechnol. Biochem. 62 (1998) 852-857
10. Isono K., Asahi K., and Suzuki S. J. Am. Chem. Soc. 91 (1969) 7490-7505
11. di Mauro, E.; Synder, L.; Marino, P.; Lamberti, A.; Coppo, A.; Tocchini-Valentini, G. P. N. Nature 1969, 222, 533-537.
12. Jacob S.T., Sajdel E.M., and Munro H.N. Nature 225 (1970) 60-62
13. Nara T., Yamamoto M., Kawamoto I., Takayama K., Okachi R., Takasawa S., Sato T., and Sato S. J. Antibiot. 30 (1977) 533-540
14. Aszalos A., Cohen A.I., Alicino J., and Keeler B.T. Antimicrob. Agents Chemother. 7 (1967) 456-463
15. Trowitzsch W., Reifenstahl G., Wray V., and Gerth K. J. Antibiot. 33 (1980) 1480-1490
16. Aoki et al. also studied the hydrolysates of cyclothiazomycin (3) in their paper describing its structural elucidation. However, they isolated this unit in lactam form despite almost identical degradation conditions. The reason for these differences is unclear.
17. Unfortunately, measurements at higher concentration did not provide useful data due to serious signal broadening as described.
18. Mocek U., Knaggs A.R., Tsuchiya R., Nguyen T., Beale J.M., and Floss H.G. J. Am. Chem. Soc. 115 (1993) 7557-7568
19. Mocek U., Zeng Z., O'Hagan D., Zhou P., Fan L.-D.G., Beale J.M., and Floss H.G. J. Am. Chem. Soc. (1993) 7992-8001
20. Satake M., Ofuji K., Naoki H., James K.J., Furey A., McMahon T., Silke J., and Yasumoto T. J. Am. Chem. Soc. 120 (1998) 9967-9968
21. +, suggesting the occurrence of hydrolysis at the aminothioacetal moiety of the 'mAla'.
22. Marfey P. Carlsberg Res. Commun. 49 (1984) 591-596
23. Bhushan R., and Brückner H. Amino Acids 27 (2004) 231-247
24. It is under investigation by collaboration with Bagley et al. They have synthesized the corresponding lactam in optically active form:. Bagley M.C., Xiong X. Org. Lett. 6 (2004) 3401-3404
25. Prior to the chemical shift predictions, structural optimization was performed employing ab initio 6-31G* for each model compound. We used Spartan '04 program by Wavefunction Inc. (18401 Von Karman Avenue, Suite 370 Irvine, CA 92612).
26. The theoretical chemical shifts predictions suggested the olefinic protons of (E)-DHHA residues appear ca. 1.0 ppm lower field than that of the corresponding (Z)-DHHA residues for other model compounds as shown below. These calculations also indicated that (Z)-DHHA residues are ca. 2.5 kcal/mol sterically more stable than the (E)-DHHA residues. These results also are consisent with our assumption for the stereochemistry of DHHA2 moiety in 1 and 2.
27. Hashimoto M., Matsumoto M., and Terashima S. Tetrahedron 59 (2003) 3041-3062
28. Davanloo P., Rosenberg A.H., Dunn J.J., and Studier F.W. Proc. Natl. Acad. Sci. U.S.A. 81 (1984) 2035-2039 {A figure is presented}
29. Melton D.A., Krieg P.A., Rebagliati M.R., Maniatis T., Zinn K., and Green M.R. Nucleic Acids Res. 12 (1984) 7035-7056
30. Zhang, X.; Studier, F. W. J. Mol. Biol. 1997, 269, 10-27.
31. Himeno H., Hanawa-Suetsugu K., Kimura T., Takagi K., Sugiyama W., Shirata S., Mikami T., Odagiri F., Osanai Y., Watanabe D., Goto S., Kalachnyuk L., Ushida C., and Muto A. Nucleic Acids Res. 32 (2004) 5303-5309
32. +. These indicated the same mass number 1472, whereas the mass formula by Cooper was one carbon smaller than that of Aoki's 3. Cooper also disclosed existences of a dehydroalanine, two dehydrohomoalamnines, three thiazolines, and three thiazoles, which are the same residues as those involved in Aoki's 3. Physical properties of our 1 and 2 were rather similar to those in Copper's report: Cooper, R.; Truumees, I.; Barrett, T.; Patel, M.; Schwartz, J.; Puar, M.; Das, P.; Pramanik, B. J. Antibiot. 1990, 43, 897.